Patients of depression with high CRP respond poorly to SSRIs: Study
Researchers at first Affiliated Hospital of Zhengzhou University, Henan, China have found in a new study based on data from more than 900 patients that individuals with depression who had high levels of C-reactive protein responded poorly to selected serotonin reuptake inhibitors compared to those with lower CRP levels.
C-reactive protein (CRP) has been shown to predict antidepressant treatment outcomes in several trials, but they were limited to small-sample and strictly-restricted conditions. This study plans to verify if CRP can predict antidepressant efficacy in large samples in the real world.
918 depressed patients who had tested CRP were included, then were followed up through their outpatient visits or by telephone to obtain information about their medication therapy (SSRIs, SNRIs, MT, NaSSA) and assess efficacy using the Clinical Global Impressions–Improvement scale (CGIsingle bondI). Efficacy was classified as effective and ineffective and CRP was separated into the low CRP group (CRP <1 mg/L, n = 709) and the high CRP group (CRP ≥1 mg/L, n = 209). The efficacy was compared in different groups.
Results
- Using Kaplan-Meier survival analysis and Cox proportional regression model to analyze, it was discovered that SNRIs were more effective than SSRIs in treating patients with high CRP and SSRIs were more effective in treating patients with low CRP than those with high CRP while no difference in efficacy between the two groups was found in patients using SNRIs, MT, NaSSA.
- Small amounts of MT and NaSSA were included, and some factors that may affect CRP value have not been controlled.
Thus, CRP could predict the efficacy of SSRIs in the real world, depressed patients with high CRP may be more likely to respond poorly to SSRIs.
Reference:
Yuqian Pan, Rui Luo, Shuqi Zhang, Yuxia Liu, Yiping Wang, Simeng Feng, Hengfen Li. C-reactive protein could predict the efficacy of SSRIs in clinical practice: A cohort study of large samples in the real world, Journal of Affective Disorders, Volume 313, 2022, Pages 251-259, ISSN 0165-0327, https://doi.org/10.1016/j.jad.2022.06.080.
Keywords:
Yuqian Pan, Rui Luo, Shuqi Zhang, Yuxia Liu, Yiping Wang, Simeng Feng, Hengfen Li, C-reactive protein, predict, efficacy, SSRIs, clinical, practice, cohort, study, large, samples, real world, Journal of Affective Disorders
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.